BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile



Five Giralda Farms

Madison  New Jersey  07940  U.S.A.
Phone: 973-660-5500 Fax: 973-660-7111


At Wyeth we have a vision of leading the way to a healthier world. We've committed ourselves to achieving this vision by making quality, integrity, and excellence the hallmarks of our business. Through recruitment, development, and motivation of the best people, we are continually growing and improving our business. We lead in innovation by linking pharmaceutical, biotechnology, and vaccine technologies.

Headquartered in Madison, New Jersey, Wyeth is one of the largest research-based pharmaceutical and health care products companies in the world. Wyeth is dedicated to solving the world's most critical health problems through research and development, spending approximately $2.1 billion in overall R&D in 2002. With annual sales of nearly $14.6 billion in 2002 and products sold in more than 140 countries, Wyeth is truly a global health care leader.

Our efforts focus on finding and developing new drugs that will enhance the quality of health care worldwide. Our discovery and development process - based on the scientific platforms of small molecules, therapeutic proteins, and vaccines - has led to innovative treatment and prevention strategies for musculoskeletal diseases, bacterial meningitis, hemophilia, and other serious threats to health worldwide.

We are committed to excellence - in the results we achieve and in how we achieve them. We pride ourselves on quality manufacturing; responsible sales, marketing, and licensing alliances; commitment to educational programs and initiatives; and service to health care professionals and patients.

We employ more than 42,000 people worldwide - each one committed to improving the health of people around the world. The diverse and talented people who work at Wyeth bring to the company a full range of talent in research, marketing, sales, and manufacturing. It is our employees who keep us on the cutting edge of innovative discoveries and superior customer service.

Lead the way to a better career at Wyeth.

 Key Statistics

Ownership: Public

Web Site: Wyeth
Employees: 42,000 worldwide
Symbol: WYE


Ligand Pharmaceuticals Inc.  - In 1994, we entered into a research and development collaboration with Wyeth-Ayerst Laboratories (now Wyeth) to discover and develop drugs that interact with estrogen and progesterone receptors for use in hormone therapy, anti-cancer therapy, gynecological diseases and central nervous system disorders associated with menopause and fertility control. Bazedoxifene, a selective estrogen receptor modulator (SERM), is the product of this collaboration.

Bazedoxifene (Viviant) is a synthetic drug that was designed to increase bone density while protecting breast and uterine tissue. Wyeth is developing bazedoxifene (Viviant) for the treatment and prevention of post-menopausal osteoporosis. FDA action on the Viviant NDA for the prevention of osteoporosis is expected in late 2007. Wyeth plans to submitted a second NDA for Viviant for the treatment of osteoporosis in 3Q07.

Wyeth is developing bazedoxifene in combination with PremarinĀ® (Aprela) as a progesterone-free treatment for menopausal symptoms including osteoporosis and hot flush. Wyeth plans to file an NDA for Aprela in late 2007.

 Company News
Ex-Wyeth (WYE) Head Out Of The Running For Sanofi (SAN.PA) CEO Gig 12/12/2014 6:18:52 AM
Too Much Hype Doomed Once-Successful Wyeth (WYE) CEO 8/1/2014 6:37:07 AM
Indian Units Of Pfizer Inc. (PFE) And Wyeth (WYE) To Merge 11/25/2013 7:38:47 AM
Pfizer Inc. (PFE) Subsidiary, Wyeth (WYE), To Redeem 5.500% Notes Due February 1, 2014 11/14/2013 9:40:15 AM
Second Tipper in Elan Corporation PLC (ELN), Wyeth (WYE) Insider Trading Case Said to be Prominent N.J. Doctor 9/6/2013 7:12:16 AM
Former Pfizer Inc. (PFE)/Wyeth (WYE) Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc. (SYN) 8/6/2013 9:47:31 AM
Pfizer Inc. (PFE) Subsidiary, Wyeth (WYE), to Redeem 5.500% Notes Due March 15, 2013 11/26/2012 10:55:04 AM
Alzheimer's Expert Leaked Inside Information on Elan Corporation PLC (ELN), Wyeth (WYE) Drug 11/21/2012 8:11:29 AM
Pfizer Inc. (PFE)'s Wyeth (WYE) Ordered to Face Class-Action Over Pristiq 9/19/2012 7:16:01 AM
Pfizer Inc. (PFE)'s Wyeth (WYE) Unit Seeks $960 Million in Damages From Sun Pharmaceutical Industries Ltd 2/16/2012 7:45:12 AM